Bismacrocyclic Inhibitors of Hepatitis C NS3/4a Protease
John A. McCauley(Merck & Co., Inc., Rahway, NJ, USA (United States)), Michael T. Rudd(United States Military Academy), Kevin T. Nguyen(United States Military Academy), Charles McIntyre(United States Military Academy), Joseph J. Romano(United States Military Academy), Kimberly J. Bush(United States Military Academy), Sándor Varga(United States Military Academy), Charles W. Ross(United States Military Academy), Steven S. Carroll(Merck & Co., Inc., Rahway, NJ, USA (United States)), Jillian DiMuzio(Merck & Co., Inc., Rahway, NJ, USA (United States)), Mark W. Stahlhut(Merck & Co., Inc., Rahway, NJ, USA (United States)), David B. Olsen(Merck & Co., Inc., Rahway, NJ, USA (United States)), Terry A. Lyle(United States Military Academy), Joseph P. Vacca(United States Military Academy), Nigel J. Liverton(United States Military Academy)
Cited by 29
Abstract
Double time: The bismacrocycle 2 was prepared from 1 by a selective double ring-closing metathesis (RCM) reaction to form the 18- and 15-membered rings simultaneously. Derivative 3 shows excellent potency against NS3/4a protease. Detailed facts of importance to specialist readers are published as ”Supporting Information”. Such documents are peer-reviewed, but not copy-edited or typeset. They are made available as submitted by the authors. Please note: The publisher is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.
Related Papers
No related papers found
Powered by citation graph analysis